What is HC Wainwright's Forecast for ELDN Q1 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Wednesday, June 18th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.32) for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals' Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.27) EPS.

Separately, Wall Street Zen lowered Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, June 6th.

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ ELDN traded down $0.06 during midday trading on Thursday, hitting $2.72. 244,846 shares of the company's stock were exchanged, compared to its average volume of 274,584. Eledon Pharmaceuticals has a twelve month low of $2.30 and a twelve month high of $5.54. The company has a market cap of $162.87 million, a PE ratio of -1.30 and a beta of -0.17. The firm's fifty day simple moving average is $3.04 and its 200-day simple moving average is $3.69.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.20.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ELDN. RA Capital Management L.P. purchased a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $14,693,000. First Light Asset Management LLC acquired a new stake in shares of Eledon Pharmaceuticals during the fourth quarter worth $9,595,000. Blue Owl Capital Holdings LP purchased a new position in Eledon Pharmaceuticals in the 4th quarter valued at $8,075,000. Sphera Funds Management LTD. grew its position in Eledon Pharmaceuticals by 96.7% in the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock valued at $10,513,000 after buying an additional 1,254,298 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in Eledon Pharmaceuticals in the 4th quarter valued at $4,848,000. Hedge funds and other institutional investors own 56.77% of the company's stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).